Malignant pleural effusion Cancer Secondary malignant neoplasm of pleura
Conditions
Interventions
Participants are randomly allocated to one of two groups:
Intervention group: Participants receive thoracic ultrasound imaging before and post talc administration.
Control group: Participants receive
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinically confident diagnosis of MPE requiring pleurodesis defined as any of the following (more than one can be included): 1.1. Histocytologically proven MPE 1.2. Thoracic CT evidence of pleural malignancy 1.3. Otherwise unexplained exudative effusion in the context of clinically proven cancer elsewhere 2. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Aged under 18 years 2. Poor prognosis (pleurodesis not offered in normal practice) 3. Irreversible contra-indication to drain insertion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Length of hospital stay (in days) during the initial hospitalisation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mortality rate is recorded at 12 months 2. Number of days in hospital post-randomisation with drain in situ 3. Patient reported dysponea/chest pain post-randomisation is measured through daily assessments for 7 days and then weekly for 4 weeks 4. Patient reported quality of life is measured using the EQ-5D-5L questionnaire at baseline, 1 and 3 months 5. Pleurodesis success is determined at 1 and 3 months 6. Use of healthcare resources and costs using utilisation logs is measured as discharge, 1 and 3 months | — |
Countries
England, United Kingdom
Contacts
Public ContactIoannis Psallidas
Outcome results
None listed